Hayley C Whitaker

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. ncbi Labeling and identification of LNCaP cell surface proteins: a pilot study
    Hayley C Whitaker
    Uro Oncology Research Group, CRUK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    Prostate 67:943-54. 2007
  2. ncbi Alterations in beta-catenin expression and localization in prostate cancer
    Hayley C Whitaker
    Uro Oncology Research Group, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    Prostate 68:1196-205. 2008
  3. ncbi The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target
    Hayley C Whitaker
    Uro Oncology Research Group, CRUK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    Prostate 70:333-40. 2010
  4. ncbi RAS pathways in prostate cancer - mediators of hormone resistance?
    Hayley C Whitaker
    Uro Oncology Research Group, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK
    Curr Cancer Drug Targets 10:834-9. 2010
  5. ncbi The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine
    Hayley C Whitaker
    Uro Oncology Research Group, CRUK Cambridge Research Institute, Cambridge, United Kingdom
    PLoS ONE 5:e13363. 2010
  6. ncbi Structural basis for the nuclear import of the human androgen receptor
    Mark L Cutress
    Uro Oncology Research Group, Cancer Research UK Cambridge Research Institute, Robinson Way, Cambridge, CB2 0RE, UK
    J Cell Sci 121:957-68. 2008
  7. ncbi Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens
    Hayley C Whitaker
    Prostate Cancer Research Group, Department of Cancer Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom
    Clin Cancer Res 10:7392-401. 2004

Detail Information

Publications7

  1. ncbi Labeling and identification of LNCaP cell surface proteins: a pilot study
    Hayley C Whitaker
    Uro Oncology Research Group, CRUK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    Prostate 67:943-54. 2007
    ..Previous studies have focused on the LNCaP whole cell proteome and transcriptome but little is known about proteins at the prostate cell membrane and how they change in response to androgens...
  2. ncbi Alterations in beta-catenin expression and localization in prostate cancer
    Hayley C Whitaker
    Uro Oncology Research Group, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    Prostate 68:1196-205. 2008
    ..A number of studies have reported the altered expression and/or localization of beta-catenin as a biomarker in prostate cancer...
  3. ncbi The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target
    Hayley C Whitaker
    Uro Oncology Research Group, CRUK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    Prostate 70:333-40. 2010
    ....
  4. ncbi RAS pathways in prostate cancer - mediators of hormone resistance?
    Hayley C Whitaker
    Uro Oncology Research Group, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK
    Curr Cancer Drug Targets 10:834-9. 2010
    ..We review the multiple lines of evidence implicating Ras as therapeutic target in androgen dependent and independent prostate cancer...
  5. ncbi The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine
    Hayley C Whitaker
    Uro Oncology Research Group, CRUK Cambridge Research Institute, Cambridge, United Kingdom
    PLoS ONE 5:e13363. 2010
    ..The promoter location of the risk allele, and its ability to reduce promoter activity, suggested that the rs10993994 risk allele could result in lowered MSMB in benign tissue leading to increased prostate cancer risk...
  6. ncbi Structural basis for the nuclear import of the human androgen receptor
    Mark L Cutress
    Uro Oncology Research Group, Cancer Research UK Cambridge Research Institute, Robinson Way, Cambridge, CB2 0RE, UK
    J Cell Sci 121:957-68. 2008
    ..Thus, in addition to its function in the nuclear import of AR, the NLS in the hinge region of AR has a separate, quite distinct role on transactivation, which becomes apparent once nuclear import has been achieved...
  7. ncbi Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens
    Hayley C Whitaker
    Prostate Cancer Research Group, Department of Cancer Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom
    Clin Cancer Res 10:7392-401. 2004
    ..This report represents the first study of the localization of wild-type AR following expression at physiologic relevant levels in prostate cells and treatment with androgen and antiandrogens...